Sugi Predict

Sugi Predict / Compounds / SCHEMBL2023347

SCHEMBL2023347

SCHEMBL2023347

COC(=O)c1ccncc1Nc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.67
▸ ALOX15 P16050 1/20 0.67
▸ KDM4E B2RXH2 5/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ ALDH1A1 P00352 4/20 0.54
▸ GLA P06280 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ KDM4C Q9H3R0 6/20 0.53
▸ PTGS1 P23219 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ HTT P42858 1/20 0.48
▸ CSNK2A1 P68400 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ AURKA O14965 1/20 0.46
▸ CXCR2 P25025 1/20 0.46
▸ KDM4D Q6B0I6 1/20 0.46
▸ HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867895 1.00 MAPT (0.67) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL21056875 0.90 KDM4E (0.61) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL21056732 0.85 L3MBTL1 (0.65) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL2021338 0.84 KDM4C (0.70) KDM4EKDM4CPTGS1PTGS2KDM4D
SCHEMBL250411 0.81 KDM4C (0.59) KDM4EALDH1A1KDM4CPTGS1PTGS2
SCHEMBL15131717 0.81 KDM4E (0.59) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL3732479 0.81 KDM4E (0.50) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL22160131 0.81 KDM4E (0.73) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL31914 0.80 MAPT (1.00) MAPTALOX15KDM4EHSD17B10ALDH1A1
SCHEMBL16542216 0.79 KDM4E (0.62) KDM4EHSD17B10ALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841459-B2 3-arylamino pyridine derivatives MERCK SERONO SA (CH) 2014-09-23 — — US claimed
US-20140051686-A1 3-Arylamino Pyridine Derivatives APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2014-02-20 — — US claimed
EP-1802579-B1 Derivatives of 3-arylaminopyridine MERCK SERONO SA (CH) 2013-11-20 — — EP claimed
US-8524911-B2 3-arylamino pyridine derivatives MERCK SERONO SA (CH) 2013-09-03 — — US claimed
US-20120295889-A1 3-Arylamino Pyridine Derivatives MERCK SERONO S.A. (CH) 2012-11-22 — — US claimed
US-8198457-B2 3-arylamino pyridine derivatives MERCK SERONO S.A. (CH) 2012-06-12 — — US claimed
US-7956191-B2 3-arylamino pyridine derivatives MERCK SERONO SA (CH) 2011-06-07 — — US claimed
US-20090093462-A1 3-Arylamino pyridine derivatives MERCK SERONO SA (CH) 2009-04-09 — — US claimed
EP-1802579-A1 3-ARYLAMINO PYRIDINE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2007-07-04 — — EP claimed
WO-2006045514-A1 3-ARYLAMINO PYRIDINE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2006-05-04 — — WO claimed
US-20240058338-A1 COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR DAY ONE BIOPHARMACEUTICALS, INC. 2024-02-22 — — US disclosed
EP-4294400-A1 COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR Day One Biopharmaceuticals, Inc. (US) 2023-12-27 — — EP disclosed
CN-117177754-A Combination of RAF inhibitors and MEK inhibitors 首日生物制药公司 2023-12-05 — — CN disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
US-20090093462-A1 3-Arylamino pyridine derivatives MERCK SERONO SA (CH) 2009-04-09 — — US disclosed
US-20090093462-A1 3-Arylamino pyridine derivatives MERCK SERONO SA (CH) 2009-04-09 — — US disclosed
US-20090093462-A1 3-Arylamino pyridine derivatives MERCK SERONO SA (CH) 2009-04-09 — — US disclosed
EP-1802579-A1 3-ARYLAMINO PYRIDINE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2007-07-04 — — EP disclosed
WO-2006045514-A1 3-ARYLAMINO PYRIDINE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295889-A1 3-Arylamino Pyridine Derivatives MAPK3, BRAF, NRAS MAPT 4533/4885ALOX15 2252/4885KDM4E 797/4885
US-20140051686-A1 3-Arylamino Pyridine Derivatives MAPK3, BRAF, NRAS MAPT 4533/4885ALOX15 2252/4885KDM4E 797/4885
US-20240058338-A1 COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR BRAF, RAF1, NRAS MAPT 3769/4885ALOX15 4177/4885KDM4E 2198/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 MAPT 3841/4885ALOX15 3025/4885KDM4E 3267/4885
US-20090093462-A1 3-Arylamino pyridine derivatives CDK4, BRAF, CDK3 MAPT 4502/4885ALOX15 2352/4885KDM4E 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback